(Reuters) -Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the ...

Volt™ PFA System enrollment wraps up, TactiFlex™ Duo trial begins, and Advisor™ HD Grid X gains FDA clearance!Portland, ...

The following is a summary of “Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes,” published in the ...

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...

The study, published Monday in the American Heart Association journal Circulation, suggests digital heart twins could offer a ...

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

BACKGROUND: Current outcomes from catheter ablation for scar-dependent ventricular tachycardia (VT) are limited by high ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.

Deutsche Bank analyst Pito Chickering upgraded the rating on Boston Scientific (BSX – Research Report) to a Buy today, setting a price target ...